糖肾安防治早期糖尿病肾病的实验研究

摘要

Objective:To investigate the preventive treatment effect and its possible mechanism of Tangshenan decoction in experimental diabetic nephrology rats. Methods:Fifty male Sprague - Dawley rats were involved, forty of which were prepared by unilateral nephrectomy, high - glucose - high - fat diet and intraperitoneal injection of STZ 35 mg/kg. Then the survived thirty six diabetic nephrology rats were randomly divided into STZ - induced diabetic nephrology( model, n = 9 ), Fosinopril - treated STZ - induced diabetic nephrology( Fosinopril, n = 9 ), Tangshenan decoction - treated STZ - induced diabetic nephrology( Tangshenan decoction, n =9 ), and joint intervention( Fosinopril + Tangshenan decoction, n = 9 )groups. The rats were sacrificed at the 6th weekend. The body weight, kidney weight, blood sugar, 24 -hour urinary protein excretion, plasma collagen Ⅳ( Col Ⅳ )concentration and the pathological change of nephridial tissue were examined. Reverse transcription polymerase chain reaction( RT - PCR ) was used to value the expression of renal transforming growth factor - (3, ( TGF - (3, ) and vascular endothelial growth factor( VEGF ) mRNA. Results:The difference of body weight, kidney weight, kidney/body weight ,blood sugar, 24 -hour urinary protein excretion, plasma collagen IV( Col IV )concentration, TGF - (3, and VEGF mRNA expression between model group and normal group were significant ( P <0. 01 ). Those differences between the three treated - group and model group are of statistical significance( P <0. 05 ). There is no statistical significance between Fosinopril group and Tangshenan decoction group in view of above differences. The renal pathological changes were observed in model group significantly, while in the three treated - group those changes were mild and there is no significant difference among them. Conclusion: The preventive treatment effect of Tangshenan decoction equivalented with Fosinopril and combinding Tangshenan decoction with Fosinopril can achieve more effective renoprotection. TGF - β1 , VEGF may be involved in the mechanism of renoprotection.%目的:研究糖肾安对早期糖尿病肾病大鼠的治疗作用并探讨其可能机制.方法:采用单肾切除、高糖高脂饲料喂养、小剂量STZ(35 mg/kg)腹腔注射"三联"方法建立糖尿病肾病大鼠模型.随机分为正常对照组、模型对照组、糖肾安组、福辛普利组、联合干预组,每组9只.用药6周后观察各组大鼠体重、肾重、血糖、24 h尿蛋白定量、血浆Ⅳ型胶原蛋白(Col Ⅳ)水平的差异及肾脏病理改变、肾脏转化生长因子-β1(TGF-β1)、血管内皮生长因子(VEGF)mRNA的表达.结果:模型组大鼠体重、肾重、肾重/体重、血糖、24 h尿蛋白定量及血浆Col Ⅳ水平、肾脏TGF-β1、VEGF mRNA表达与正常对照组比较,差异均有统计学意义(P<0.01);各用药组上述指标有所改善,与模型组比较差异均有统计学意义(P<0.05).糖肾安组与福辛普利组比较上述指标差异均没有统计学意义.肾脏病理变化以模型组最为明显,系膜细胞重度增生,各用药组均有不同程度减轻.结论:糖肾安对早期糖尿病肾病具有良好的防治作用,其效果与福辛普利相当,中西医结合治疗能取得更好的效果.其肾保护作用可能是通过影响肾脏促纤维化生长因子TGF-β1、VEGF表达实现的.